Ícone: Impressão reduzida.  Print

CURRICULUM VITAE

Fernanda Marques photo.

Name: Fernanda
Surnames: Marujo Marques
Born: 21-06-1955, Lisboa, Portugal
Nationality: Portuguese

Phone: +351-21 994 6225
Fax: +351-21 994 6185
E-mail: fmarujo (@itn.pt)

Education

  • 1993 – PhD in Biochemistry, Faculdade de Ciências, Universidade de Lisboa (FCUL).

  • 1978 – Graduate in Chemical Engineering, Instituto Superior Técnico (IST), Universidade Técnica de Lisboa.

Professional Employment Career

  • 1994-1998 – Executive Director of Laboratório Central de Análises, Universidade de Aveiro.
  • 1994-......  – Researcher, Instituto Tecnológico e Nuclear (ITN).
  • 1985-1994 – Assistant Researcher, Instituto Nacional de Engenharia e Tecnologia Industrial (INETI).

  • 1982-1985 – Trainee Researcher, Laboratório Nacional de Tecnologia Industrial (LNETI).

Training

  • 09/10/2002-09/10/2003 – Development of genotoxicity and cytotoxicity assays, Departamento de Genética, Faculdade de Ciências Médicas da Universidade Nova de Lisboa.
  • 02/12-09/12/1989 – Development of radioimmunoassays, St. Bartholomews Hospital, London, England.

  • 01/04-30/04/1988 – Development radioimmunoassay, Institute of Hungarian Academy of Sciences, Budapest, Hungary.

Membership of Professional Societies

  • Member of the Sociedade Portuguesa de Bioquímica.

Main Scientific Area of Research

  • Development of radiopharmaceuticals: synthesis and biological evaluation of radioactive complexes.

Other Scientific Areas of Interest

  • Biochemistry: transduction mechanisms and hormonal modulation at cellular level.

  • Molecular and Cellular Biology.

Teaching Activities

  • Collaboration in the Master course "Química Inorgânica Biomédica" (ITN-FCUL), 2004-....
  • Collaboration in the Training in Radiopharmacy of Technical Nuclear Medicine Course students, ESTST, Lisbon, 2001-....

Participation in Projects

  • "17a-[125I]iodovinyl steroids substituted at 7a: Investigation of new series of [125I]-labelled estrogens as potential imaging agent for estrogen receptor-positive breast cancers": PRAXIS/PSAU/C/SAU/89/96.
  • "Radiopharmaceuticals for Treatment of Bone Pain and/or Therapy Based on Macrocyclic Lanthanide Complexes": POCTI/35859/SAU/99, March 2002-March 2005.
  • "Evaluation of the Genotoxic and Antiestrogenic Potential of Triphenylethylene Derivatives and their Metabolites": POCTI/33544/QUI/99, October 2000-October 2004.
  • "Quality of skin as a Barrier to Ultra-Fine Particles (NANODERM)": EC Shared COST RTD ACTION: QoL-2002-2004.
  •  "Multicomponent technetium and gallium metallointercalators for targeted radiotherapy": POCTI/QUI/57632/2004.
  •  "Novel estrogen receptor ligands as potential probes for targeted tumour imaging and therapy": CIMAGO-2005-2007.

Collaborations with other Institutions

  • Laboratório de Genética, Centro de Metabolismo e Endocrinologia, Faculdade de Medicina de Lisboa.
  • Instituto Biomédico de Investigação da Luz e Imagem (IBILI), Coimbra.
  • Institute of Advanced Material Study, Kyushu University, Fukuoka, Japan.
  • Departamento de Genética, Faculdade de Ciências Médicas, Universidade Nova de Lisboa.
  • Departamento de Química, Faculdade de Ciências, Universidade do Porto.

Prizes

  •  Prize Ernesto Roma-Boehringer Mannheim (1997) – Portuguese original research work in the area of diabetes mellitus.

Selected Publications

  • Palladium-109: a new radiocolloid. M. Neves and F. Marques, Int. J. Applied Radiation and Isotopes, 35, 546-547, (1984).
  • Coupling of a sheep anti-T3 IgG to a solid phase for a triiodotironine radioimmunoassay. I. Santos, F. Marques and L. Patrício, J. Radioanalytical and Nuclear Chemistry, articles 102 143-148, (1986).
  • Palladium-109 and Holmium-166 potential radionuclides for synoviotherapy-radiation absorbed dose calculations. M. Neves, F. Marques and L. Patrício, Int. J. Applied Radiation and Isotopes, 38, 745-749, (1987).
  • Holmium-166: a potential lanthanide element in radiotherapy. M. Neves, M. Reis, E. Martinho, F. Marques and L. Patrício, Inorganica Chimica Acta, 140, 359-360, (1987).
  • Control of NADH ferricyanide reductase activity in the human erythrocyte by somatotrophin and insulin. F. Marques, M. E. Crespo and M. Bicho, Redox Report 1, 113-117, (1995).
  • Conversion of adrenaline to indolic derivatives by the human erythrocyte plasma membrane. F. Marques, R. O. Duarte, J. J. G. Moura and M. Bicho, Biological Signals, 5, 275-282, (1996).
  • Insulin activation of NADH ferricyanide reductase in human erythrocytes is mediated by the insulin receptor tyrosine kinase: a comparative study in normal and diabetic states, F. Marques, M. E. Crespo, O. Pantaleão e M. Bicho, Redox Report 2, 373-378, (1996).
  • Activation of a NADH dehydrogenase in the human erythrocyte by beta-adrenergic agonists: possible involvement of a G protein in enzyme activation. F. Marques and M. P. Bicho, Biological Signals, 6, 52-61, (1997).
  • Activação por hormonas peptídicas de uma NADH ferricianeto redutase no eritrócito humano. M. E. Crespo, F. Marques, Z. I. Silva and M. Bicho, Endocrinologia Metabolismo & Nutrição, 6, 225-230, (1997).
  • Redox modulation of reductase and phosphatase activities in the human erythrocytes”. F. Marques, M. E. Crespo, Z. I. Silva and M. Bicho, Protoplasma, 206, 168-173, (1999).
  • Insulin and high glucose modulation of phosphatase and reductase enzymes in the human erythrocytes. A comparative analysis in normal and diabetic states, F. Marques, M. E. Crespo, Z. I. Silva e M. Bicho, Diabetes Research and Clinical Practice, 47 191-198, (2000).
  • 153Sm and 166Ho complexes with tetraaza macrocycles containing pyridine and methylcarboxylate or methylphosphonate pendant arms, F. Marques, K. P. Guerra, L. Gano, J. Costa, M. P.Campello, L. M .P. Lima, R. Delgado and I. Santos, J. Biol. Inorg. Chem., 9, 859-872, (2004).
  • Radiopharmaceuticals for targeted radiotherapy. F. Marques, A. Paulo, M. P. Campello, S. Lacerda, R. F. Vitor, L. Gano, R. Delgado and I. Santos, Radiation Protection Dosimetry, 116, 601-604, (2005).
  • 13- and 14- membered macrocyclic ligands containing methylcarboxylate or methylphosphonate pendant arms: chemical and biological evaluation of their 153Sm and 166Ho complexes as potential agents for therapy or bone pain palliation. F. Marques, L. Gano, M. P.Campello, S. Lacerda, I. Santos, L. M. P. Lima, J. Costa, P. Antunes and R. Delgado, J. Inorg. Biochem., 100, 270-280, (2006).
  • Radiochemical and biological behaviour of 153Sm and 166Ho complexes anchored by a novel bis(methylphosphonate) tetraazamacrocycle. M. P.Campello, F. Marques, L. Gano, S. Lacerda and I. Santos, Radiochimica Acta (in press).
  • Biological evaluation of 153Sm and 166Ho complexes with tetraazamacrocycles containing methylcarboxylate and/or methylphosphonate pendant arms. F. Marques, L. Gano, M. P.Campello, S. Lacerda and I. Santos, Radiochimica Acta (in press).

     

Page back